Danish Multiple Sclerosis Center - Neurological Department, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9 Copenhagen 2100, Denmark.
Expert Rev Neurother. 2013 Dec;13(12):1309-17. doi: 10.1586/14737175.2013.859523.
Fampridine is indicated to improve walking in adult multiple sclerosis (MS) patients. Indications vary between countries and the prescribing neurologist should be aware of the labeling and indication in his own country. The prolonged-release formulation of 4-aminopyridine has reduced the risk of seizure to a level near the intrinsic MS risk, and the risk can be further minimized if it emphasized that patients should not exceed the recommended dose of 10 mg twice a day, should not catch up on missed doses and should not divide, crush or chew tablets. It is imperative to check the renal function before and during treatment and make sure the patient does not get concomitant medications affecting the renal elimination. The use of fampridine is considered safe, and the side effects are often mild and acceptable. Approximately one-third of MS patients treated with fampridine will experience an improvement of their walking speed above 20% on the timed 25-foot walk test (T25FW), which is considered to be clinically relevant.
盐酸苯丙哌林可改善成年多发性硬化症（MS）患者的行走能力。其适应证因国家而异，开处方的神经科医生应了解其本国的标签和适应证。4-氨基吡啶的缓释制剂已将癫痫发作的风险降低到接近 MS 固有风险的水平，如果强调患者不应超过每日两次、每次 10 毫克的推荐剂量，不应补服漏服的剂量，不应分割、压碎或咀嚼片剂，则可进一步降低风险。在治疗前和治疗期间务必检查肾功能，并确保患者未同时使用影响肾清除的药物。盐酸苯丙哌林的使用被认为是安全的，其副作用通常是轻微的且可以接受的。大约三分之一接受盐酸苯丙哌林治疗的 MS 患者在 25 英尺计时步行测试（T25FW）中的行走速度会提高 20%以上，这被认为具有临床意义。
